The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves
about
SV2 mediates entry of tetanus neurotoxin into central neuronsSNAP-23 and VAMP-3 contribute to the release of IL-6 and TNFα from a human synovial sarcoma cell lineSV2 renders primed synaptic vesicles competent for Ca2+ -induced exocytosisEmerging opportunities for serotypes of botulinum neurotoxinsBotulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neuronsTNFα induces co-trafficking of TRPV1/TRPA1 in VAMP1-containing vesicles to the plasmalemma via Munc18-1/syntaxin1/SNAP-25 mediated fusion.Glycosylated SV2 and Gangliosides as Dual Receptors for Botulinum Neurotoxin Serotype FA Single-Domain Llama Antibody Potently Inhibits the Enzymatic Activity of Botulinum Neurotoxin by Binding to the Non-Catalytic α-Exosite Binding RegionCrystal Structure of the Botulinum Neurotoxin Type G Binding Domain: Insight into Cell Surface BindingBotulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent mannerStructural analysis of the receptor binding domain of botulinum neurotoxin serotype DThe biological activity of botulinum neurotoxin type C is dependent upon novel types of ganglioside binding sitesBotulinum Neurotoxin Is Shielded by NTNHA in an Interlocked ComplexStructure of dual receptor binding to botulinum neurotoxin BCrystal Structures of Botulinum Neurotoxin DC in Complex with Its Protein Receptors Synaptotagmin I and IIIdentification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin AAtoxic derivative of botulinum neurotoxin A as a prototype molecular vehicle for targeted delivery to the neuronal cytoplasmExtraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies.Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain.Botulinum neurotoxin devoid of receptor binding domain translocates active protease.Onset dynamics of type A botulinum neurotoxin-induced paralysis.Lipid and cationic polymer based transduction of botulinum holotoxin, or toxin protease alone, extends the target cell range and improves the efficiency of intoxicationEffect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium.Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins.Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.SV2 acts via presynaptic calcium to regulate neurotransmitter release.Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodiesPreferential entry of botulinum neurotoxin A Hc domain through intestinal crypt cells and targeting to cholinergic neurons of the mouse intestineSNARE tagging allows stepwise assembly of a multimodular medicinal toxin.What next for botulism vaccine development?Tetanus toxin entry. Nidogens are therapeutic targets for the prevention of tetanus.Presynaptic enzymatic neurotoxins.Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxinBotulinum neurotoxin type A is internalized and translocated from small synaptic vesicles at the neuromuscular junction.A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic.In vivo neutralization of botulinum neurotoxins serotype E with heavy-chain camelid antibodies (VHH).Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A).Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discoveryAssociation of botulinum neurotoxin serotype A light chain with plasma membrane-bound SNAP-25
P2860
Q21090499-A72458D1-920E-424C-9F07-16F32DBFF320Q24316444-11AA1A8C-619A-4115-807C-D5EC6FDA5D8AQ26269919-0272A60D-946E-462D-98D7-A700CF254689Q26859917-BAAED06E-FBDB-4CD7-9D93-2F6D31BBCF97Q27339199-14823A13-AC2D-4CDF-9A4E-66E17CB392CAQ27348801-615EDEB4-4081-4ED5-9510-E43C0C483272Q27655649-7743DDE1-FBBC-4268-81CC-48813742C58EQ27659624-9A0BCF3A-4919-414B-A4B2-42FEED83815AQ27660172-BADFBFC0-12E3-43EF-9DDB-D8D9D12278B9Q27664044-5F613467-F086-45A1-AEB2-A09C1557D8EBQ27664616-B9CC13C1-18AC-42AE-B80B-1F2A64E8BD73Q27667683-9D5EDA90-900F-43E0-98CA-51C04AB8B017Q27677462-60422F49-CA09-4601-B8C3-60CCAEF69706Q27678834-F845CD5A-049A-4F47-83EE-9F5431636C68Q27679493-F4BA14A9-1EED-4AE3-9164-8574FC3880A5Q28581589-17D1EF0B-9DFE-436F-88AF-89D29A4E15F2Q28660367-90481ED3-2D21-4386-9542-C2290494552AQ30862040-E1E88D96-C1F1-43A6-9877-A47204F4876CQ33261279-BF5C92E8-31C0-4AFE-98D3-97CAB916C698Q33361666-40337F39-AE8E-4202-B30C-1A4EA72C2D63Q33394567-3F0FB5E2-879A-4703-968D-EC4B3EEDD8ADQ33557078-99A4D8C7-E868-4025-976E-51FC08CEC162Q33620738-A8255A73-2930-49CF-BB66-227E84270989Q33671401-8FF8CD46-187F-4DED-88C8-55B26BCB410AQ33793263-75D8E3D2-CBC5-4656-AFEB-C1608D80CFA2Q33869062-AC8D4DBA-048F-4DD5-8D2F-EC85015821AAQ34034957-01F02D51-638C-4DC2-9CD9-CD8C5C6A431CQ34074842-458C3459-70FE-4E06-B359-8EC4DBD031EAQ34205889-32DE5F7E-B3D0-46B2-8A4C-2BD84164F489Q34241315-D7E93B24-7C3D-48AA-997C-2115698D3279Q34343808-AA33ACCF-5EC8-4EB4-A5F6-4BBC1A6CA310Q34449930-D4AAE02E-EA5D-4E67-AB39-5113A23E7818Q34542589-9AC30785-2FB9-46CB-9EE4-9641EAAEFDFFQ34571717-B400184F-A965-404D-9CD9-043426711EF0Q34614163-ACD7BA14-E2D6-4B49-AD86-4BF481FD2A9AQ34675649-7B5B6036-CE81-48FB-8089-0BAFD6657948Q34716360-7CD209BA-B025-470E-A214-B24BDC084B9DQ34733600-340FC4EC-8B42-4BBE-A837-93237648007EQ34850583-36070F56-724E-43A7-B970-E02B4DBC419FQ34868904-E67D2452-7CE5-4CAF-8BDD-905BB580BC22
P2860
The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves
description
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2006
@ast
im April 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2006/04/03)
@sk
vědecký článek publikovaný v roce 2006
@cs
wetenschappelijk artikel (gepubliceerd op 2006/04/03)
@nl
наукова стаття, опублікована у квітні 2006
@uk
مقالة علمية (نشرت في 3-4-2006)
@ar
name
The synaptic vesicle protein 2 ...... urotoxin A into phrenic nerves
@ast
The synaptic vesicle protein 2 ...... urotoxin A into phrenic nerves
@en
The synaptic vesicle protein 2 ...... urotoxin A into phrenic nerves
@nl
type
label
The synaptic vesicle protein 2 ...... urotoxin A into phrenic nerves
@ast
The synaptic vesicle protein 2 ...... urotoxin A into phrenic nerves
@en
The synaptic vesicle protein 2 ...... urotoxin A into phrenic nerves
@nl
prefLabel
The synaptic vesicle protein 2 ...... urotoxin A into phrenic nerves
@ast
The synaptic vesicle protein 2 ...... urotoxin A into phrenic nerves
@en
The synaptic vesicle protein 2 ...... urotoxin A into phrenic nerves
@nl
P2093
P3181
P1433
P1476
The synaptic vesicle protein 2 ...... urotoxin A into phrenic nerves
@en
P2093
Bazbek Davletov
Hans Bigalke
Stefan Mahrhold
Thomas Binz
P304
P3181
P356
10.1016/J.FEBSLET.2006.02.074
P407
P577
2006-03-07T00:00:00Z